{
    "clinical_study": {
        "@rank": "53647", 
        "acronym": "PIP-SBT", 
        "arm_group": {
            "arm_group_label": "xin te mie", 
            "arm_group_type": "Experimental", 
            "description": "1.5-3.0g,iv,bid or tid for 7-14 days"
        }, 
        "brief_summary": {
            "textblock": "In the proposed study, the investigators plan to evaluate the efficacy and safety of\n      Piperacillin sodium and sulbactam sodium for injection (2:1) for the treatment of\n      respiratory and urinary tract acute bacterial infection under the widely used in clinical\n      conditions."
        }, 
        "brief_title": "Piperacillin Sodium and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Respiratory Tract Infections", 
            "Urinary Tract Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Respiratory Tract Infections", 
                "Urinary Tract Infections"
            ]
        }, 
        "detailed_description": {
            "textblock": "Piperacillin sodium and sulbactam sodium for injection (2:1) plays a therapeutic role by the\n      former inhibiting bacterial cell wall synthesis by irreversible competitive inhibition of\n      \u03b2-lactamase. The antimicrobial effect of cefotaxime can be enhanced by the two combined. The\n      compound specifically aims to the mechanism of bacterial resistance, extending the life of\n      Piperacillin in the treatment-resistant pathogen infections."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. patients who qualify for moderate and severe acute respiratory or urinary tract\n             bacterial infection of acute bacterial infections need for systemic antibiotic\n             therapy.\n\n          2. Age>18 years old, Gender: both\n\n          3. Women of childbearing age were to be negative pregnancy test and agree to take\n             contraceptive measures during the trial;\n\n          4. patients were volunteers and signed informed consent form;\n\n          5. patients did not participate in other clinical trials.\n\n        Exclusion Criteria:\n\n          1. Patients were hypersusceptibility to the test drug or other penicillins ,\u03b2-lactamase\n             inhibitor\n\n          2. Pregnant and Lactating women\n\n          3. Patients  have severe liver,kidney,cardiovascular,cerebrovascular,endocrine and\n             hematopoietic system of primary diseases  and that of  immunodeficiency,advanced\n             cancer or mental illness.\n\n          4. Patients who were complicated by other diseases and thought to affect efficacy\n             evaluations or poor compliance."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "2000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01897831", 
            "org_study_id": "2002 H L 0153"
        }, 
        "intervention": {
            "arm_group_label": "xin te mie", 
            "description": "durg:Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) 1.5-3.0g,iv,bid for 7-14 days Serious infections:6.0-12.0g,iv,tid for 7-14 days", 
            "intervention_name": "xin te mie", 
            "intervention_type": "Drug", 
            "other_name": [
                "te mie jun", 
                "xin ke jun"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Piperacillin", 
                "Sulbactam"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Piperacillin Sodium and sulbactam sodium", 
            "Phase IV clinical studies", 
            "Respiratory and urinary tract infections"
        ], 
        "lastchanged_date": "July 9, 2013", 
        "number_of_arms": "1", 
        "official_title": "A Open Multi-center Clinical Study on Piperacillin Sodium and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection", 
        "overall_official": {
            "affiliation": "Chongqing Red Cross Hospital", 
            "last_name": "changqing cq li, doctor", 
            "role": "Study Director"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "end of treatment of bacteriological efficacy(bacterial clearance)\nThe fore-and-aft changes of clinical symptoms and signs after discontinuation of drugs", 
            "measure": "overall effect", 
            "safety_issue": "No", 
            "time_frame": "two year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01897831"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "the incidence(%)of allergies, skin rashes, shock,death, etc.", 
            "measure": "Number of participants with Adverse Events", 
            "safety_issue": "No", 
            "time_frame": "two year"
        }, 
        "source": "Xiangbei Welman Pharmaceutical Co., Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Xiangbei Welman Pharmaceutical Co., Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2011", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}